PhenQ Announces Official Website Update Featuring Enhanced User Experience and Easier Access to Metabolic Support Resources
PhenQ , a global wellness brand dedicated to supporting weight management and metabolic health, has officially updated its website to provide users with an improved experience and simplified access to its trusted supplement offerings. The redesign reflects PhenQ's continued focus on user accessibility, faster navigation, and easier product discovery.
According to the official site (www.phenq.com), the update introduces a streamlined homepage layout, optimized mobile responsiveness, and enhanced search features—allowing visitors to explore wellness resources, customer FAQs, and product insights with greater ease.
'We reimagined the user experience to make it easier for our community to access the information and tools they need,' said a PhenQ spokesperson. 'The updated interface ensures customers can learn about our approach to natural weight support with clarity and confidence.'
The redesign also includes an upgraded checkout process, faster loading times, and an expanded Help Center. Visitors can now more efficiently explore PhenQ's educational articles, access order tracking, and engage with customer support through newly integrated live chat and FAQ navigation tools.
The company states that this digital refresh is part of a broader initiative to enhance global wellness accessibility through online platforms, aligning with the brand's mission to support healthy lifestyles via intuitive, user-friendly resources.
As highlighted on the website, PhenQ continues to offer a satisfaction guarantee for new customers. With improved tools and responsive support now built into the site, users can expect a more streamlined journey from education to product exploration.
About PhenQ
PhenQ is a globally recognized wellness brand committed to delivering natural, easy-to-integrate supplements that support metabolic health and weight management. Focused on simplicity, transparency, and digital accessibility, PhenQ empowers adults to pursue wellness goals with confidence.
Product and Contact Information
Brand: PhenQ
Website: https://phenq.com
Email: [email protected]
Phone (U.S.): +1 888-643-8434 (4am–6pm EST)
Phone (UK): +44 20 4572 5840 (9am–11pm GMT)
Mailing Address: 12 Payne Street, Glasgow G4 0LF, United Kingdom
Disclaimer
This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
FDA Issues Most-Serious Risk Warning for Cucumber Recall
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The federal Food and Drug Administration (FDA) has classified a series of recalls for cucumber featuring products, all produced by Houston-based company JFE Franchising Inc., as Class I; this means consuming any item risks causing "serious adverse health consequences or death." Newsweek contacted JFE Franchising Inc. for comment on Saturday via online inquiry form outside of regular office hours. Why It Matters The official FDA website says that a Class I recall means there is "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death." What To Know The recalls were initially issued for products containing cucumbers that "have the potential to be contaminated with Salmonella" and applies to products distributed to Alabama, Illinois, Indiana, Kentucky, Michigan, Tennessee and Wisconsin. The initial recalls took place voluntarily at the manufacturer's request in cooperation with the FDA and were announced on May 20, 2025. Products covered by the recall were all sold in plastic containers under the SNOWFRUIT or SNOWFOX label, and their respective retail numbers are: Fruit & Vegetable Tray—64 oz. 63912394047 Family Garden Salad—24 oz. 63912388065 Garden Salad—12 oz. 63912388067 Family Cobb Salad—22 oz. 63912388068 Cobb Salad—11 oz. 63912388069 Chef Salad—11 oz. 63912395033 Cucumber with Ranch—9 oz. 63912395020 Cucumber, Lime & Tajin—19oz 63912388053 Mixed Melon, Cucumbers & Tajin—18oz 63912394007 Watermelon & Cucumber w/ Tajin—18oz 63912394036 Small Vegetable Tray—19.5 oz. 63912388045 Small Party Tray with Dip—19 oz. 63912388046 Large Vegetable Tray—42 oz. 63912388056 Cucumber Slices w/Tajin—15 oz. 63912388022 Vegetable Bowl—26 oz. 63912388044 Cucumber Bowl w/ Ranch Dressing—15 oz. 63912388063 Vegetable Bowl—13 oz. 63912388072 Baby Carrot, Cucumber, & Ranch—15 oz. 63912394045 Cucumber Salad—3oz 63912389243 Spicy Cucumber Salad—3oz 63912389329 Bibimbap Bowl—13 oz. 63912389259 Yaki Noodle Bowl—12 oz. 63912389254 Ebi Vermicelli Bowl—13oz 63912389334 Sushi containing cucumber—Various price, weight and UPCs—Made daily with a one-day shelf life, already expired. The recall also applies to a number of products sold at Roundy's or Weis Market retail locations. These are: Signature Vegetable Bowl—28 oz. 639123600172 Chef Salad—16 oz. 639123600295 Cobb Style Salad—15 oz. 639123600318 Garden Salad—16 oz. 639123600547 Greek Salad—16 oz. 639123600523 Cucumber Salad—3oz 63912389205 Consumers with impacted SNOWFRUIT or SNOWFOX products are advised not to consume them but instead to return them to the place of purchase for a refund. Those with questions can contact the brands via hello@ or hello@ Stock photo: A sliced-up cucumber is seen on a chopping board, May 26, 2011 in Hamburg, Germany. Stock photo: A sliced-up cucumber is seen on a chopping board, May 26, 2011 in Hamburg, Germany. Joern Pollex/GETTY In its initial recall notice, the FDA said no illnesses related to the products had been recorded thus far. Separately, the FDA has issued a recall notice for Peak Cocktails, a popular ready-to-drink alcohol-free cocktail brand, over fears their cans could burst unexpectedly. Wegmans Semi-Sweet Chocolate Nonpareils have been recalled from stores in eight states and Washington, D.C., due to undeclared milk allergens, which the company warned could be "life-threatening" for some people. Costco has recalled Danby brand U-shaped window Air Conditioners sold between June 10, 2021 and February 2, 2022, with customers urged to stop using the products immediately. What People Are Saying The FDA said: "Salmonella is an organism that can cause serious and sometimes-fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. "In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis. Symptoms of salmonellosis usually start 6 hours to 6 days after infection and last 4 to 7 days." What Happens Next Anyone who has purchased products covered by the recall are urged to dispose of them or return them to the place of purchase for a full refund.
USA Today
13 hours ago
- USA Today
That cucumber recall? You might want to check your fridge
Salmonella infects 1.35 million people every year. One expert said recalls are the last line of defense. Does it feel like there have been lots of cucumber recalls lately? You are not wrong. The Food and Drug Administration has classified 137 potential salmonella recall reports for food products containing cucumbers in 2025, more than in any other year with available data. The Centers for Disease Control and Prevention has linked cucumbers to a current salmonella outbreak. Salmonella bacteria are a major cause of foodborne illness, infecting 1.35 million people and killing 420 people each year. Since 2012, the Food and Drug Administration has classified over 3,200 salmonella food reports, according to federal data. On average, a salmonella recall lasts nearly a year, a USA TODAY review of the FDA data found. Currently, there are 217 salmonella recall reports ongoing. You can explore the products here: The FDA has the authority to mandate a recall, but about 99% are voluntarily issued by the companies that make the products. After a recall is initiated, the agency classifies the health hazard presented by the product from Class I (a reasonable probability that the product will cause serious adverse health consequences or death) to Class III (the product is not likely to cause adverse health consequences). About 44% of food recall reports have been classified as Class I. On the other hand, 80% of salmonella food reports are classified as Class I. Most people get infected with salmonella by eating contaminated food like raw or undercooked meat, poultry, eggs, raw or unpasteurized milk and other dairy products, and produce. According to the CDC, 1 in 25 packages of chicken in the grocery store is contaminated with salmonella. Department of Human and Health Services Secretary Robert Kennedy Jr. is among the many promoting raw milk, but experts caution against it. 'We have people whose families have had children and parents and others sickened after drinking raw milk,' said Sandra Eskin, CEO at the nonprofit Stop Foodborne Illness. 'It has salmonella in it, it can have E. coli, and it can have any number of pathogens. That's why they invented pasteurization.' Warmer weather can also create ideal conditions for the bacteria to grow, so it's recommended to refrigerate perishable foods. Other sources of salmonella include contaminated water and the handling of animals. Symptoms start within six hours to six days from the time of exposure and include fever, diarrhea, nausea, vomiting and stomach pain. Most people recover within 4 to 7 days without treatment, but some cases lead to hospitalization and death. Since the start of President Donald Trump's second term, there have been severe cuts and the federal health services workforce is expected to drop from 82,000 to 62,000, USA TODAY previously reported. Trump argued the cuts are a way to save taxpayers' money, but experts say allocating resources towards food safety is critical. An FDA spokesperson told USA TODAY in an email statement that the agency prioritizes food safety and is committed to working with all stakeholders. 'The layoffs relate to administrative staff positions in the FDA. There has been no impact to operational investigators conducting food safety inspections,' the FDA spokesperson said. Over a decade ago, when annual salmonella numbers were estimated to be lower, the U.S. Department of Agriculture estimated that foodborne illness cost the country $3.7 billion per year, most of which was attributed to premature deaths. Eskin, who previously worked at the U.S. Department of Agriculture overseeing food safety and inspections, said recalls are essential for public health. 'A recall is the last line of defense that you and I have to prevent getting sick,' Eskin said, 'if we're going to a restaurant, or more importantly, going to the grocery store.' Dr. Susan Kansagra, chief medical officer at the Association of State and Territorial Health Officials, said in an email statement that federal funds support a wide range of state-level activities related to foodborne illness, like laboratory testing, case reporting, and guiding providers and the public on prevention and treatment. 'Loss of funding and staffing decreases our national capacity to do these activities and therefore quickly detect and respond to foodborne illness,' Kansagra said.
Yahoo
a day ago
- Yahoo
U.S. Leads North America Syringe Infusion Pumps Market Amid Rising Hospitalizations and Chronic Diseases
The North America Syringe Infusion Pumps Market is projected to grow from USD 645.1 million in 2024 to USD 1.04 billion by 2030, at a CAGR of 8.40%. Key drivers include an increase in chronic diseases and surgeries, technological advancements, and the expansion of home healthcare. The market is bolstered by favorable regulations and major regional growth. North American Syringe Infusion Pumps Market Dublin, July 04, 2025 (GLOBE NEWSWIRE) -- The "North America Syringe Infusion Pumps Market Size, Share & Trends Analysis Report by Disease Indication (Pediatrics/neonatology, Chemotherapy, Diabetes, Gastroenterology), End-use (Hospitals, Homecare), Country with Growth Forecasts, 2025-2030" report has been added to North America Syringe Infusion Pumps Market was valued at USD 645.1 million in 2024, and is projected to reach USD 1.04 billion by 2030, rising at a CAGR of 8.40%. The market is experiencing substantial growth driven by the increasing prevalence of chronic diseases, affecting approximately six in ten adults and necessitating precise, continuous medication delivery for conditions such as cancer and diabetes. The rising number of surgical procedures and ICU admissions further amplifies demand for these pumps, crucial for delivering anesthetics and critical care medications. This is especially true considering the projected increase in U.S. hospitalizations from 36 million in 2025 to 40 million by advancements in smart infusion technologies, including Dose Error Reduction Systems (DERS) and EHR compatibility, are pivotal in enhancing medication safety and efficiency, as North America leads in their adoption. The expanding home healthcare and ambulatory care sectors, fueled by an aging population and cost-containment strategies, are increasing the demand for portable, user-friendly syringe pumps for safe medication delivery outside hospitals. Favorable regulatory environments and reimbursement policies further support the sustained growth and innovation within the America Syringe Infusion Pumps Market Report Highlights: Pediatrics/neonatology held the largest revenue share of over 25% in 2024, owing to the critical need for precise drug delivery for newborns and infants, coupled with advancements in safety technologies and NICU/PICU investments The chemotherapy segment is projected to grow at the fastest CAGR over the forecast period Market growth is fueled by the critical need for precise syringe pump delivery of potent drugs, supported by safety features, and the increasing number of cancer cases. Hospitals dominated the market with around 40.0% of the total revenue share in 2024 due to high demand for precise drug delivery in critical care and diverse applications. Homecare is projected to grow at the fastest CAGR of 8.7% over the forecast period. The U.S. dominated the North American syringe infusion pumps market, supported by the high prevalence of chronic diseases and growing national healthcare expenditure. Companies Featured The major companies featured in this North America Syringe Infusion Pumps market report include: Baxter B. Braun Medical Inc. Fresenius Kabi AG ICU Medical, Inc. Micrel Medical Devices SA Boston Scientific Corporation BD Terumo Corporation Moog Inc. IRadimed Corporation CODAN Companies ACROMED Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $645.1 Million Forecasted Market Value (USD) by 2030 $1040 Million Compound Annual Growth Rate 8.4% Regions Covered North America Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.3. Competitive InsightsChapter 3. North America Syringe Infusion Pumps Market Variables, Trends & Scope3.1. Market Lineage Outlook3.2. Market Dynamics3.3. North America Syringe Infusion Pumps Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.2. PESTEL AnalysisChapter 4. North America Syringe Infusion Pumps Market: Disease Indication Estimates & Trend Analysis4.1. Disease Indication Segment Dashboard4.2. North America Syringe Infusion Pumps Market: Disease Indication Movement Analysis4.3. North America Syringe Infusion Pumps Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)4.4. Chemotherapy4.5. Diabetes4.6. Gastroenterology4.7. Analgesia/Pain Management4.8. Pediatrics/Neonatology4.9. Hematology4.10. OthersChapter 5. North America Syringe Infusion Pumps Market: End Use Estimates & Trend Analysis5.1. End Use Segment Dashboard5.2. North America Syringe Infusion Pumps Market: End Use Movement Analysis5.3. North America Syringe Infusion Pumps Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)5.4. Hospitals5.5. Homecare5.6. Others (ASC, Nursing Homes, Rehabilitation Centers)Chapter 6. North America Syringe Infusion Pumps Market: Country Estimates & Trend Analysis6.1. Country Market Dashboard6.2. Country Market Share Analysis, 2024 & 20306.3. North America Syringe Infusion Pumps Market by country: Key Takeaways6.4. U.S.6.5. Canada6.6. MexicoChapter 7. Competitive Landscape7.1. Recent Developments & Impact Analysis, By Key Market Participants7.2. Company/Competition Categorization7.3. Vendor Landscape7.3.1. Key company heat map analysis, 20247.4. Company Profiles Baxter B. Braun Medical Inc. Fresenius Kabi AG ICU Medical, Inc. Micrel Medical Devices SA Boston Scientific Corporation BD Terumo Corporation Moog Inc. IRadimed Corporation CODAN Companies ACROMED For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Syringe Infusion Pumps Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
